Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Lilly taps ProQR for RNA editing

by Ryan Cross
September 18, 2021 | A version of this story appeared in Volume 99, Issue 34

 

Eli Lilly and Company is partnering with ProQR Therapeutics to develop up to five RNA-editing therapies for genetic diseases of the liver and nervous system. ProQR is one of several firms designing oligonucleotides that recruit a human enzyme called ADAR to make single-nucleotide changes in RNA. In August, Roche partnered with Shape Therapeutics to develop similar RNA-editing systems. ProQR will get $50 million up front and milestone payments of up to $1.25 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.